Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 9/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896220 | 0.87 | TP53 (0.68) | TP53LMNAMAPTPOLBMEN1 | |
| SCHEMBL16896231 | 0.86 | POLB (0.68) | TP53LMNAMAPTPOLBMEN1 | |
| SCHEMBL16896044 | 0.85 | POLB (0.67) | TP53LMNAMAPTPOLBMEN1 | |
| SCHEMBL16896230 | 0.83 | TP53 (0.73) | TP53LMNAMAPTPOLBMEN1 | |
| SCHEMBL16896113 | 0.83 | LMNA (0.68) | TP53LMNAMAPTPOLBMEN1 | |
| SCHEMBL16896210 | 0.83 | TP53 (0.68) | TP53LMNAMAPTPOLBMEN1 | |
| SCHEMBL16896201 | 0.81 | TP53 (0.69) | TP53LMNAMAPTPOLBMEN1 | |
| SCHEMBL16896205 | 0.81 | TP53 (0.64) | TP53LMNAMAPTPOLBMEN1 | |
| SCHEMBL16903565 | 0.80 | MAPT (0.80) | TP53LMNAMAPT | |
| SCHEMBL16896188 | 0.80 | POLB (0.76) | TP53LMNAMAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372499-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | THE JOHNS HOPKINS UNIVERSITY | 2023-11-23 | — | — | US | disclosed |
| US-20230372499-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | THE JOHNS HOPKINS UNIVERSITY | 2023-11-23 | — | — | US | disclosed |
| US-20230233696-A1 | TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230226199-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Ashvattha Therapeutics, Inc. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226199-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Ashvattha Therapeutics, Inc. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20210170040-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | PROGRAMMABLE MEDICINE OPERATING COMPANY | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372499-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | TIE1, FLT3, FLT1 | TP53 1339/4885LMNA 3585/4885MAPT 3762/4885 |
| US-20230233696-A1 | TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF | FUT6, FUT5, OGT | TP53 1172/4885LMNA 1019/4885MAPT 2695/4885 |
| US-20230226199-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | TIE1, FLT3, FLT1 | TP53 1339/4885LMNA 3585/4885MAPT 3762/4885 |
| US-20210170040-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | TIE1, FLT3, FLT1 | TP53 1339/4885LMNA 3585/4885MAPT 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.